Cookie-Settings

We use cookies to give you the best experience possible with our website and to improve our communication with you. We consider your selection and will only use the data you have approved us to gather.

Necessary cookies

These cookies help making a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

Statistics cookies

These cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. With this information we can constantly improve the experience we offer on our website.

Marketing cookies

These cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.

DE
  • Home
  • About medac
  • Information for patients
  • Healthcare professionals
  • Products
  • Career opportunities
  • Media
  • Medac at the EBMT 2019

    Innovative conditioning therapy for MDS and AML

    During the medac satellite symposium at this year’s 45th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Prof. Franco Locatelli, from Rome in Italy stated that there is a great need for conditioning treatments that simultaneously offer the maximum antileukaemic effects and reduced toxicity. An innovative treatment option from medac is about to be granted marketing authorisation in Europe.1

     


    1medac press release from 14.12.2018: „New conditioning therapy by medac about to receive European approval“

    Nach oben